Symptomatic Control of Neuroendocrine Tumors with Everolimus

被引：0
|
作者：
Bainbridge, H. [1 ]
Larbi, E. [2 ]
Middleton, G. [2 ]
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Royal Surrey Cty Hosp, Guildford, Surrey, England
来源：
NEUROENDOCRINOLOGY | 2012年 / 96卷
关键词：
neuroendocrine; carcinoid; everolimus; symptom;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [41] When Should Everolimus Be Administered in the Natural History of Pancreatic Neuroendocrine Tumors? Reply
    Yao, James C.
    Voi, Maurizio
    Lincy, Jeremie
    Pavel, Marianne
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (13) : 1488 - +
  • [42] Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus
    Cella, C. A.
    Barberis, M.
    Spada, F.
    Pisa, E.
    Laffi, A.
    Gritti, S.
    Leone, I
    Zanetti, C.
    Fazio, N.
    NEUROENDOCRINOLOGY, 2018, 106 : 4 - 4
  • [43] Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
    Sciammarella, Concetta
    Luce, Amalia
    Riccardi, Ferdinando
    Mocerino, Carmela
    Modica, Roberta
    Berretta, Massimiliano
    Misso, Gabriella
    Cossu, Alessia Maria
    Colao, Annamaria
    Vitale, Giovanni
    Necas, Alois
    Fedacko, Jan
    Galdiero, Marilena
    Correale, Pierpaolo
    Faggiano, Antongiulio
    Caraglia, Michele
    Capasso, Anna
    Grimaldi, Anna
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [44] Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations
    Liu, Eric
    Marincola, Paula
    Oberg, Kjell
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2013, 6 (05) : 412 - 419
  • [45] Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors
    Noura Benslama
    Julien Bollard
    Cécile Vercherat
    Patrick Massoma
    Colette Roche
    Valérie Hervieu
    Julien Peron
    Catherine Lombard-Bohas
    Jean-Yves Scoazec
    Thomas Walter
    Investigational New Drugs, 2016, 34 : 654 - 662
  • [46] The role of the activation of mTOR pathway in patients with advanced neuroendocrine tumors treated with everolimus
    Gelsomino, F.
    Rossi, G.
    Spallanzani, A.
    Bertolini, F.
    Fontana, A.
    Tamma, V. A.
    Zironi, S.
    Depenni, R.
    Di Emidio, K.
    Luppi, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 139 - 139
  • [47] Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
    Viudez, Antonio
    Crespo, Guillermo
    Dorronsoro, Maria Luisa Gomez
    Arozarena, Imanol
    Marin-Mendez, Juan Jesus
    Custodio, Ana
    Benavent, Marta
    Goni, Saioa
    Garcia-Paredes, Beatriz
    Hern, Jorge
    Durantez, Maika
    Alonso, Vicente
    Riesco, Del Carmen
    Lopez, Carlos
    Jimenez-Fonseca, Paula
    San Vicente, Borja Lopez
    Gonzalez-Borja, Iranzu
    Sevilla, Isabel
    Hernandez-Garcia, Irene
    Carmona-Bayonas, Alberto
    Capdevila, Jaume
    Perez-Sanz, Jairo
    Garcia-Carbonero, Rocio
    Perez-Ricarte, Leyre
    Llanos, Marta
    Vera, Ruth
    De Jesus Acosta, Ana
    PANCREATOLOGY, 2021, 21 (01) : 215 - 223
  • [48] Enhancing Efficacy of PRRT for Neuroendocrine Tumors by Combining With Everolimus and Histone Deacetylase Inhibitors
    Lee, Dongyoul
    Li, Mengshi
    Liu, Dijie
    Kapoor, Somya
    Prindle, Joshua
    Smith, Addelynn
    Schultz, Michael
    PANCREAS, 2019, 48 (03) : 444 - 444
  • [49] Clinical Impact of Everolimus Cumulative Dose on Pancreatic Neuroendocrine Tumors (pNETs) Outcome
    Berardi, R.
    Torniai, M.
    Onofri, A.
    Partelli, S.
    Guglielmi, S.
    Gucciardino, C.
    Savini, A.
    Ferretti, B.
    Enrica, T.
    Giustini, L.
    Falconi, M.
    Cascinu, S.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 275 - 275
  • [50] Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors
    Benslama, Noura
    Bollard, Julien
    Vercherat, Cecile
    Massoma, Patrick
    Roche, Colette
    Hervieu, Valerie
    Peron, Julien
    Lombard-Bohas, Catherine
    Scoazec, Jean-Yves
    Walter, Thomas
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (05) : 654 - 662
12345